-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Roche Diagnostics China (hereinafter referred to as "Roche Diagnostics") announced that it has reached a strategic partnership with Changchun Sinomed Medical Technology Co.
, Ltd.
RS600 automated assembly line
.
It is understood that the Roche Group was founded in 1896.
Roche is headquartered in Basel, Switzerland.
Based on research and development, it aims to provide each patient with a targeted treatment plan through personalized medicine
.
After more than 100 years of development, the Roche Group's business has spread to more than 100 countries around the world
.
It is worth noting that since entering the Chinese market in 2000, Roche Diagnostics has always adhered to the concept of "based on the world and deeply cultivated in China", and is committed to introducing more advanced in vitro diagnostic solutions into China
.
At the same time, the company is also actively exploring innovative business models with local companies through strategic cooperation to jointly promote the construction of an integrated ecosystem of diagnosis and treatment
.
It is understood that as early as November 8, 2021, Shenzhen Baimingsheng Medical Equipment Co.
, Ltd.
(a wholly-owned subsidiary of Changhong Technology) signed the "Strategy" with "Roche Diagnostics" at the 4th China International Import Expo in Shanghai.
Cooperation Framework Agreement, and jointly work on cooperation in the fields of wide application of polymer material technology such as diagnostic consumables and diagnostic reagent packaging
.
As for the joint construction of RS600 automated assembly line with Sinomed, the industry generally believes that it is another pioneering exploration and attempt between Roche Diagnostics and local excellent enterprises
.
In addition to Roche Diagnostics, in fact, in recent years, the "wave of cooperation" between domestic and foreign pharmaceutical companies has begun to emerge
.
For example, on January 18, Eli Lilly announced that it had entered into a global cooperation and exclusive license agreement with Heyu Medicine to further target undisclosed targets in major diseases with unmet medical needs, such as cardiometabolic diseases, in novel Collaborate on the discovery, development and potential commercialization of small molecule drugs
.
Prior to this, Lilly also reached a cooperation with Shanghai Ruige Medicine.
The two parties will cooperate closely in preclinical drug development, clinical research and commercialization in the next few years to jointly develop innovative treatments for metabolic diseases
.
Among the many multinational companies, Pfizer deserves special mention.
.
It is reported that from the 10th to the 11th of this year, it announced a number of important cooperations, including the introduction of a number of technologies to supplement the product pipeline, and the use of AI technology to promote the development of anti-cancer and other drugs
.
The analysis believes that with China's continuous efforts in deepening the reform of the medical and health system, the construction of the universal medical insurance system and the improvement of the hierarchical diagnosis and treatment system have achieved remarkable results; and people's demand for medical and health care is increasing day by day, and it presents a multi-level and diversified upgrade.
Looking at the situation, cooperation between domestic and foreign pharmaceutical companies will become more frequent in the future
.
It is expected that through these cooperation, companies can achieve greater complementarity of advantages, share risks, and flexibly mobilize resources from both parties in the future, so as to better promote the research and development of new products, accelerate the commercialization process, and benefit more patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, Ltd.
RS600 automated assembly line
.
It is understood that the Roche Group was founded in 1896.
Roche is headquartered in Basel, Switzerland.
Based on research and development, it aims to provide each patient with a targeted treatment plan through personalized medicine
.
After more than 100 years of development, the Roche Group's business has spread to more than 100 countries around the world
.
It is worth noting that since entering the Chinese market in 2000, Roche Diagnostics has always adhered to the concept of "based on the world and deeply cultivated in China", and is committed to introducing more advanced in vitro diagnostic solutions into China
.
At the same time, the company is also actively exploring innovative business models with local companies through strategic cooperation to jointly promote the construction of an integrated ecosystem of diagnosis and treatment
.
It is understood that as early as November 8, 2021, Shenzhen Baimingsheng Medical Equipment Co.
, Ltd.
(a wholly-owned subsidiary of Changhong Technology) signed the "Strategy" with "Roche Diagnostics" at the 4th China International Import Expo in Shanghai.
Cooperation Framework Agreement, and jointly work on cooperation in the fields of wide application of polymer material technology such as diagnostic consumables and diagnostic reagent packaging
.
As for the joint construction of RS600 automated assembly line with Sinomed, the industry generally believes that it is another pioneering exploration and attempt between Roche Diagnostics and local excellent enterprises
.
In addition to Roche Diagnostics, in fact, in recent years, the "wave of cooperation" between domestic and foreign pharmaceutical companies has begun to emerge
.
For example, on January 18, Eli Lilly announced that it had entered into a global cooperation and exclusive license agreement with Heyu Medicine to further target undisclosed targets in major diseases with unmet medical needs, such as cardiometabolic diseases, in novel Collaborate on the discovery, development and potential commercialization of small molecule drugs
.
Prior to this, Lilly also reached a cooperation with Shanghai Ruige Medicine.
The two parties will cooperate closely in preclinical drug development, clinical research and commercialization in the next few years to jointly develop innovative treatments for metabolic diseases
.
Among the many multinational companies, Pfizer deserves special mention.
.
It is reported that from the 10th to the 11th of this year, it announced a number of important cooperations, including the introduction of a number of technologies to supplement the product pipeline, and the use of AI technology to promote the development of anti-cancer and other drugs
.
The analysis believes that with China's continuous efforts in deepening the reform of the medical and health system, the construction of the universal medical insurance system and the improvement of the hierarchical diagnosis and treatment system have achieved remarkable results; and people's demand for medical and health care is increasing day by day, and it presents a multi-level and diversified upgrade.
Looking at the situation, cooperation between domestic and foreign pharmaceutical companies will become more frequent in the future
.
It is expected that through these cooperation, companies can achieve greater complementarity of advantages, share risks, and flexibly mobilize resources from both parties in the future, so as to better promote the research and development of new products, accelerate the commercialization process, and benefit more patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
